Sponsors (5)
The bill directs DoD to study and report on potential psilocybin-based therapy access for servicemembers—offering a pathway to expand treatments and better coordinate agencies while raising medical risk, readiness, legal, privacy, and cost concerns.
Servicemembers with treatment-resistant PTSD and similar patients could gain a formally explored pathway to access psilocybin-based therapy, potentially expanding clinical treatment options.
DoD would compile safety, dosing, and adverse-event data in a formal report, providing information to inform safer clinical use and oversight for military patients.
Veterans and servicemembers transitioning from DoD to VA care could see improved continuity and reporting for investigational therapies, reducing gaps in treatment during transitions.
Servicemembers offered investigational Schedule I psilocybin-based treatments could face unknown medical risks and adverse events.
Operational use in deployed or high-readiness units could degrade medical readiness if treatments have acute side effects or require monitoring.
Relying on Right-to-Try or emergency-authority pathways could bypass full FDA approval processes, creating legal, liability, and ethical questions for patients and DoD/VA providers.
Based on analysis of 2 sections of legislative text.
Directs DoD to report within 180 days on safety, dosing, legal pathways, and readiness implications of a 2026 psilocybin PTSD trial and propose steps for pilot activities beginning FY2027.
Official title: To direct the Secretary of Defense to submit to Congress a report on emerging investigational treatment options for treatment-resistant post-traumatic stress disorder in veterans, members of the Armed Forces, and members transitioning to civilian life, and for other purposes.
Introduced June 30, 2026 by Abraham J. Hamadeh · Last progress June 30, 2026
Requires the Assistant Secretary of Defense for Health Affairs to prepare and deliver a detailed report within 180 days about a 2026 clinical trial of whole‑mushroom psilocybin for PTSD, focusing on safety, dosing, adverse events, operational relevance, and implications for force health protection, medical readiness, and suicide prevention. The report must evaluate legal/regulatory pathways for any expanded access to an investigational Schedule I substance, consider applicability of Federal Right to Try and relevant executive orders, and assess continuity of care between military and VA systems, plus workforce, infrastructure, budget implications, and a proposed timeline for pilot activities starting FY2027.